Study of Prognostic Biomarkers of Survival at 6 Months for Patients Treated With Bevacizumab Glioblastomas in First Relapse After Failure of Radiochemotherapy

Inclusion criteria

• Patients, between 18 and 88 years, with glioblastoma (histologically proven) in first relapse after conventional treatment by surgery and temozolomide and radiotherapy
• Biological Criteria

• Polymorphonuclear neutrophils> 1500 / mm3
• Plates> 100,000 / mm3
• SGOT-SGPT <5 at the upper limit of normal (ULN)
• Bilirubin <1.5 x ULN
• Creatinine <1.5 LSN and creatinine clearance
• Proteinuria <1 g / 24 hours
• Patient with health insurance
• Consent signed by the patient if he is lucid, or failing that by the person of trust

Exclusion criteria

• Patients who can not benefit from bevacizumab for the following reasons:

• Symptomatic cerebral or tumor hemorrhage
• Karnofsky Index less than 50% or
• Patients already treated with an antiangiogenic molecule or Gliadel (diagnosis and recurrence).
• Coagulation disorders in case of injectable treatment (especially for avastin),
• Contraindications known to the MRI: Pace Makers, foreign bodies intraocular, electrodes ...
• Uncontrolled severe concomitant pathology, including another evolving cancer (with the exception of operative cutaneous tumors, in situ cancer of the cervix or breast treated).
• Uncontrolled Infection
• Uncontrolled hypertension (PAS> 160 mm Hg) despite optimized treatment
• Coronary artery disease or unstable arterial disease. Evolutionary aneurysm.
• Myocardial infarction dating from less than 6 months.
• Peripheral arterial or cerebrovascular accident occurring less than 6 months.
• Heart Failure> grade II NYHA
• Hemorrhagic Disease (Hemophilia, Willebrandt ...)
• Nephrotic syndrome with proteinuria> 2 g / 24 h
• History of haemoptysis dating less than 1 month.
• Pulmonary embolism dating less than 1 month.
• Surgical intervention (other than craniotomy or stereotactic biopsy) dating less than one month or essential and predictable surgery.
• History of digestive fistula or intestinal perforation with resolution less than 6 months.
• Hypersensitivity to bevacizumab or to any of the excipients mentioned in Composition.
• Hypersensitivity to Chinese hamster ovary (CHO) cells or to other human or humanized recombinant antibodies.
• Severe Myelosuppression
• Pregnant or nursing. Contraception should be prescribed if necessary during treatment.
• Persons deprived of liberty or placed under safeguard of justice (guardianship or curatorship),
• Subject involved in another search including an exclusion period still in progress at pre-inclusion
• Patient refusing to participate in the study